All patients with IgAN in Cohort 1 have transitioned to subcutaneous (SC) dosing, and BION-1301 remains well-tolerated, with no serious adverse events (SAEs) and no treatment discontinuations due to adverse… Read More
The Newly Founded Company, Epitopea, Has Secured $14 Million in Seed Financing to Advance the Ground-breaking Tumor-Specific Antigen (TSA) Research of Drs. Claude Perreault and Pierre Thibault at the Université… Read More
TORONTO – adMare BioInnovations is pleased to announce the appointment of Dr. Christine Allen as Vice-President, Ecosystem Development. Dr. Allen will continue adMare’s leadership of Canada’s strong life sciences ecosystem through… Read More
More than 500 industry leaders, SMEs representatives, policy makers and academia are expected in Vilnius, Lithuania to join Europe’s leading event on industrial biotechnology and the bioeconomy under the title… Read More
Approval Marks Numinus’ First use of Psilocybin-Assisted Therapy Treatment Outside of Clinical Trials VANCOUVER, BC –Numinus Wellness Inc. (“Numinus”) (TSX: NUMI) (OTC: NUMIF), a mental health care company advancing innovative treatments… Read More
